Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background EXSCEL is a randomized, double‐blind, placebo‐controlled trial examining the effect of exenatide once‐weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk. Methods Patients were enrolled at 688 sites in 35 countries. We describe their baseline characteristics according to prior CV event status and compare patients with those enrolled in prior glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) outcomes trials. Results Of a total of 14,752 participants randomized between June 2010 and September 2015, 6,788 (46.0%) patients were enrolled in Europe; 3,708 (25.1%), North America; 2,727 (18.5%), Latin America; and 1,529 (10.4%), Asia Pacific. Overall, 73% had at least one prior CV event (70% coronary artery disease, 24% peripheral arterial disease, 22% cerebrovascular disease). The median (IQR) age was 63 years (56, 69), 38% were female, median baseline HbA1c was 8.0% (7.3, 8.9) and 16% had a prior history of heart failure. Those without a prior CV event were younger with a shorter duration of diabetes and better renal function than those with at least one prior CV event. Compared with prior GLP‐1RA trials, EXSCEL has a larger percentage of patients without a prior CV event and a notable percentage who were taking a dipeptidyl peptidase‐4 inhibitor at baseline (15%). Conclusions EXSCEL is one of the largest global GLP‐1RA trials, evaluating the safety and efficacy of EQW with a broad patient population that may extend generalizability compared to prior GLP‐1RA trials (ClinicalTrials.gov number, NCT01144338).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“outcomes trials with only a primary hypothesis of non-inferiority.(4,5) In the present manuscript, we describe the baseline characteristics of EXSCEL participants”
BackgroundMethodResultSelf-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 6×
“In the recent large-scale T2DM outcomes trial with the DPP-4 inhibitor saxagliptin (SAVOR), there were observations of increased hospitalization for HF.14,15 Increased hospitalization for HF has not been observed consistently with other DPP-4 inhibitors indicating the lack of a class effect.”
BackgroundInfluentialLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“outcomes trials with only a primary hypothesis of non-inferiority.(4,5) In the present manuscript, we describe the baseline characteristics of EXSCEL participants”
MethodSelf-citationFitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationScirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Cited by
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Self-citationFudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99
Self-citationClegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94
Self-citationGreene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“EXSCEL (2017) (26) GLP-1 receptor agonists 14,752 Yes Not described 16.”
BackgroundFuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Metadata
- Authors
- Mentz, R. J., Bethel, M. A., Gustavson, S., Thompson, V. P., Pagidipati, N. J., Buse, J. B., Chan, J. C., Iqbal, N., Maggioni, A. P., Marso, S. P., Ohman, P., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A. F., & Holman, R. R.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 187
- Pages
- 1-9
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2588615098
- Cited by
- 64
- References
- 8
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). https://app.cochat.ai/papers/10.1016/j.ahj.2017.02.005
- The paper
- Mentz, R. J., Bethel, M. A., Gustavson, S., Thompson, V. P., Pagidipati, N. J., Buse, J. B., Chan, J. C., Iqbal, N., Maggioni, A. P., Marso, S. P., Ohman, P., Poulter, N., Ramachandran, A., Zinman, B., Hernandez, A. F., & Holman, R. R. (2017). Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). American Heart Journal. https://doi.org/10.1016/j.ahj.2017.02.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.